

Rising inflation has been the talk of the town in 2022 and S&P/ASX 200 Index (ASX: XJO) shares aren’t immune from its bite.
In fact, many ASX 200 technology shares have been hit hard by the shifting landscape. The S&P/ASX 200 Information Technology Index (ASX: XIJ), for example, has plunged nearly 38% year to date.
So, which ASX 200 shares can investors trust to grow their hard-earned money in 2022?
Head of Australian equities at T. Rowe Price, Randal Jenneke has flagged two stocks he believes have plenty of pricing power and could act as inflation hedges.
2 ASX 200 shares to buy in times of inflation
There are two likely ways Australiaâs current inflationary environment could shift, according to Jenneke.
The first â and most unlikely direction â is towards 1970s-style “stagflation”. The more likely happening? Inflation continuing to rise through 2022.Â
“The challenge of rising costs, whether labour or other inputs, will likely persist and contribute to higher headline inflation over the rest of the year,” Jenneke said.
“[W]e will likely see investor focus shift more from top line revenue growth to margin sustainability and their volatility. We have already seen the valuation gap between high margin and high growth narrow.”
And companies with strong pricing power are the most prepared to manage through such a period.
“To pass on costs effectively to buyers requires a good industry structure, differentiated products, and defensive volumes,” Jenneke said.
Resmed CDI (ASX: RMD)
Fortunately, ASX 200 healthcare share Resmed has just that. Jenneke said:
Resmed ⦠has a large under-penetrated market, and despite various input and logistics cost pressures, has been able to pass through price increases given their dominant market share and current lack of reputable competition.
The Resmed share price is currently $30.91, 14.5% lower than it was at the start of 2022.
Transurban Group (ASX: TCL)
ASX 200 infrastructure share Transurban is also set up to battle inflation, according to Jenneke, who said:
Transurban ⦠has built-in price increases for its contracts.
The nature of its cost structure brings high [earnings before interest and tax (EBIT)] margins and margin stability. Anecdotally, you know the cost of tolls are rising when every second taxi driver makes a point or two about it.
The Transurban share price is $14.45 right now, having gained 3.6% year to date.
Finally, the expert noted, “while these are two [shares] we like, we should stress our views are supported by our fundamental insights, rather than the broader economic climate.”
The post 2 ASX 200 shares with enough pricing power to battle inflation: Expert appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now
See The 5 Stocks
*Returns as of June 1 2022
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Broker rates these 2 top ASX 200 shares as buys in July
- Why is the Transurban share price languishing today?
- Hoping to bag the next Transurban dividend? Read this
- Brokers name 2 ASX dividend shares to buy next week
- Why Goldman Sachs sees 13% upside for the ResMed share price
Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/TGn0Swr
Leave a Reply